PT-141 trials found desire benefits in certain women

The prescription treats lost desire that troubles women before menopause

Scientists developed PT-141, or bremelanotide, to change desire through the brain. Vyleesi is the approved prescription for certain women troubled by their lost desire before menopause. These women lost previously normal desire across partners and settings. Approval doesn't cover men, women past menopause or general performance claims ^[21], and a PT-141 research bottle doesn't share that approval.

Two Phase 3 trials, large tests in people before approval, followed 1,267 women. Over 24 weeks, desire improved and related distress eased beyond what chance alone would readily explain ^[19]. A 52-week follow-up included 684 women continuing treatment ^[20]. Benefits continued, without a new safety concern appearing during that follow-up.

Nausea, headache and flushing were the most common drug-related problems. Flushing means the face or skin feels warm and looks red. Those harms matter when you weigh the reported desire benefit. A PT-141 research product's name can't prove the contents meet prescription drug standards.

A research name cannot prove the contents match the prescription

Bremelanotide contains seven amino acids, small pieces that also form proteins. The parts form a ring resembling a natural hormone. The drug changes brain activity linked to desire and arousal. Drugs acting on blood-vessel muscle elsewhere in the body work differently.

PT-141 was the name used during bremelanotide's development and research. Approval covers prescription shots for women whose lost desire causes distress and who haven’t reached menopause ^[21]. Other groups don't share that approved use. Nor can the name tell you what an unregulated bottle contains, the strength of the contents or whether impurities are present.

The names PT-141 and bremelanotide both identify the same active substance here, but the substance's name cannot establish whether another product contains that substance or meets prescription drug standards. The prescription product passed checks under drug rules. You can't assume research material passed those checks merely because the name matches.

Brain changes in women did not settle a separate animal question

Researchers think bremelanotide partly affects dopamine, a chemical carrying messages between brain cells. Dopamine can affect desire and emotion. A brain-scan study compared treatments in 31 women before menopause ^[18]. Neither women nor staff knew which treatment was given; brain activity changed and desire increased for up to 24 hours.

A separate study tested female Syrian hamsters ^[17]. Researchers looked at brain cells involved in dopamine and at sexual reward. They found no added sign that the hamsters found sexual activity rewarding. The animal test asked about reward rather than relief from lost desire in women.

That animal test left one proposed explanation for the drug's action unproven. The animal finding can't tell you how women feel during treatment, because brain scans explore brain activity while treatment trials ask whether women gain relief from the problem being treated. Neither a scan nor an animal experiment can replace those treatment results.

Women’s desire and distress ratings improved beyond the placebo results

The main treatment trials. Two Phase 3 RECONNECT trials, large tests before approval, included 1,267 women who haven’t reached menopause and are troubled by low desire. Over 24 weeks, desire and related distress improved more with bremelanotide than placebo, an inactive treatment used for comparison ^[19]. Chance alone was unlikely to explain those differences. The ratings don't count how many women were cured or predict your response.

Continued treatment. A 52-week follow-up included 684 women who knew they received bremelanotide. Benefits continued without a new safety concern. Nausea affected 40.4%, flushing affected 20.6%, and headache affected 12.0% ^[20]. Flushing means warmth and redness of skin; without a placebo comparison, expectations could affect women's ratings.

Brain scans and desire. Another study tested 31 women before menopause ^[18]. Brain responses changed while the women viewed sexual material. Increased desire lasted up to 24 hours. This test explored how the drug acts rather than replacing treatment trials.

2025: a hamster test. Researchers found no added sign of sexual reward in female hamsters ^[17]. The test asked a different question from relief for women. An animal's behavior can't measure a woman's desire or distress. The hamster finding leaves that animal explanation unproven.

Brief pressure rise and the heart warnings. The official drug instructions warn of a brief blood-pressure rise ^[21]. Known heart disease rules out use. Uncontrolled high blood pressure also rules out use. Those warnings remain even though the medicine has an approved purpose.

Nausea, skin changes and a pressure rise can accompany treatment

People using bremelanotide for research describe experiences; a fair treatment trial hasn't checked these accounts, and patients share reports too. Some mention stronger desire or arousal, while others notice no benefit. Nausea is the problem mentioned most often. Accounts also describe headaches, tingling, tiredness, sore shot sites, skin or gum darkening, and flushing, meaning warm red skin.

Men's accounts concern people outside the group covered by approval. People decide which experiences to share, so the reports leave gaps. The accounts can't show you how often everyone experiences an effect. Nor can the accounts prove what a bottle contained or establish the cause of a reported change.

In the 52-week follow-up, nausea affected 40.4%, flushing 20.6%, and headache 12.0% ^[20]. Instructions rule out treatment with known heart disease or uncontrolled high blood pressure because pressure can rise briefly ^[21]. Repeated treatment can darken skin patches ^[21]. Approval concerns women who haven’t reached menopause and feel distressed by loss of previously normal desire across partners and settings ^[21].

Men, women past menopause and general performance claims remain outside approval. Research bottles add uncertainty about the substance and strength actually present. You can't assume those contents passed the prescription drug's checks. The name alone doesn't establish benefit or safety in another group.

Desire ratings cannot rank bremelanotide against weight medicines

PT-141 names bremelanotide without establishing every bottle's quality. The medicine has Phase 3 trials, large treatment tests, and a certain approved use ^[19][21]. The approval doesn't extend to research material outside prescription drug rules. Your reading of a claim needs the actual product as well as the drug name.

Bremelanotide trials asked women about desire and the distress of losing desire. Sugar and growth-hormone medicines were tested for different health problems. Those findings can't place all four medicines in a best-to-worst order. The comparison page sets out who was tested, the benefits and possible harms.